Personalised cancer vaccines represent one of the most promising advances in immuno-oncology, offering the potential for highly targeted and effective treatments.
Moving these therapies from research into the clinic remains challenging, with progress often constrained by common barriers across the regenerative therapy ecosystem.
Key challenges include effective mRNA delivery, access to advanced lipid nanoparticle (LNP) formulations, and manufacturing technologies that can support early stage clinical production at small scale.
Addressing these issues requires cross sector collaboration and open exchange of expertise.
Hear from SMART CRC partner organisation Cytiva in a webinar that that focuses on the technical and manufacturing considerations shaping the future of personalised cancer vaccines.
The session brings together insights on formulation science, delivery innovation, and small scale manufacturing approaches tailored to clinical translation.
By integrating these perspectives, the webinar highlights how aligned formulation and manufacturing strategies can help smooth the transition from concept to clinic, reducing bottlenecks that slow promising therapies.
Initiatives like this enable shared learning and collaboration across industry and research and are vital to strengthening the ecosystem.
SMART CRC recognises that collective progress is essential to advancing personalised cancer vaccines and accelerating impact for patients.
Find out more, here